A clinician's guide to ADHD treatment options. (Q53132267)

11 May 2018

title

A clinician's guide to ADHD treatment options. (English)

1 reference

11 May 2018

author name string

Gregory W Mattingly

series ordinal

1

1 reference

11 May 2018

Joshua Wilson

series ordinal

2

1 reference

11 May 2018

Anthony L Rostain

series ordinal

3

1 reference

11 May 2018

language of work or name

English

0 references

publication date

1 August 2017

1 reference

11 May 2018

published in

Postgraduate Medicine

1 reference

11 May 2018

volume

129

1 reference

11 May 2018

issue

7

1 reference

11 May 2018

page(s)

657-666

1 reference

11 May 2018

What have we learnt about the causes of ADHD?

cites work

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003-2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

The World Health Organization Adult Attention-Deficit/Hyperactivity Disorder Self-Report Screening Scale for DSM-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-Onset Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Gender differences in adult attention-deficit/hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

ADHD prevalence in adult outpatients with nonpsychotic psychiatric illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Adults With Persistent ADHD: Gender and Psychiatric Comorbidities-A Population-Based Longitudinal Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Distinguishing comorbidity and successful management of adult ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Changes in the Definition of ADHD in DSM-5: Subtle but Important

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Improving Communication in ADHD Care: Results from In-office Linguistic Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Attention Deficit Hyperactivity Disorder and adult mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

The risk of injury in adults with attention-deficit hyperactivity disorder: A nationwide, matched-cohort, population-based study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

The impact of ADHD on the health and well-being of ADHD children and their siblings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Childhood Attention-Deficit/Hyperactivity Disorder and Future Substance Use Disorders: Comparative Meta-Analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Motor Vehicle Crash Risk Among Adolescents and Young Adults With Attention-Deficit/Hyperactivity Disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Self-reported ADHD and adjustment in college: cross-sectional and longitudinal findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Adolescent ADHD and adult physical and mental health, work performance, and financial stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Functional and psychosocial impairment in adults with undiagnosed ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Callous-unemotional traits, proactive aggression, and treatment outcomes of aggressive children with attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Medication for attention deficit-hyperactivity disorder and criminality

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Attention-deficit hyperactivity disorder comorbidity and antidepressant resistance among patients with major depression: A nationwide longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Methyiphenidate vs. amphetamine: Comparative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Safety and efficacy considerations due to misuse of extended-release formulations of stimulant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

ADHD, stimulant treatment, and growth: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Attention-deficit/hyperactivity disorder with inadequate response to stimulants: approaches to management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Toward quality care in ADHD: defining the goals of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Pharmacological interventions for ADHD: how do adolescent and adult patient beliefs and attitudes impact treatment adherence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Pharmacokinetics of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Children with Attention-Deficit/Hyperactivity Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Olanzapine orally disintegrating tablet: a review of efficacy and compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

A randomized crossover study to assess the pharmacokinetics of a novel amphetamine extended-release orally disintegrating tablet in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Skin tolerability associated with transdermal drug delivery systems: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

Medication Adherence and Symptom Reduction in Adults Treated with Mixed Amphetamine Salts in a Randomized Crossover Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/00325481.2017.1354648

10.1080/00325481.2017.1354648

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018